CareDx, Inc (NASDAQ:CDNA) Shares Sold by Marshall Wace LLP

Marshall Wace LLP trimmed its stake in CareDx, Inc (NASDAQ:CDNA - Free Report) by 21.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 289,457 shares of the company's stock after selling 78,973 shares during the quarter. Marshall Wace LLP owned about 0.54% of CareDx worth $6,197,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of CDNA. Thompson Davis & CO. Inc. boosted its position in shares of CareDx by 6.3% in the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after buying an additional 950 shares during the period. Legal & General Group Plc boosted its holdings in CareDx by 1.3% in the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock worth $1,922,000 after acquiring an additional 1,118 shares during the period. Sterling Capital Management LLC grew its position in CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of CareDx by 6.5% during the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares during the period. Finally, Plato Investment Management Ltd boosted its stake in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after purchasing an additional 1,370 shares during the period.

CareDx Price Performance

Shares of NASDAQ:CDNA traded down $0.41 during trading on Monday, reaching $18.07. 599,219 shares of the company's stock traded hands, compared to its average volume of 800,222. The stock has a market capitalization of $1.00 billion, a P/E ratio of -6.70 and a beta of 2.18. CareDx, Inc has a 12 month low of $7.61 and a 12 month high of $34.84. The company has a 50 day moving average of $19.07 and a 200-day moving average of $21.81.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million for the quarter, compared to analysts' expectations of $84.56 million. Equities research analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CDNA. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and decreased their price objective for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright dropped their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group reduced their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.